Foundation Medicine to Identify Patients Eligible for National Cancer Institute’s NCI-MATCH (Molecular Analysis for Therapy Choice) Study

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine (NASDAQ: FMI) today announced a collaboration with the National Cancer Institute (NCI) and ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) for their precision medicine cancer trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131). This ongoing study is evaluating the benefit of genomically-guided treatments targeting specific alterations within a person’s tumor, regardless of cancer type. Foundation Medicine will notify physicians at the more than 1,100 clinical sites participating in NCI-MATCH when the comprehensive genomic profiling (CGP) assays they ordered to guide clinical care, FoundationOne® or FoundationOne® Heme, reveal findings that may make a patient eligible for one of several NCI-MATCH treatments.